$899 – $1,399

3rd Global Congress on Cancer Immunology and Epigenetics (AAC)

Event Information

Share this event

Date and Time



Venue will be informed to the Registered Participants


San Francisco, 94103

View Map

Event description
3rd Global Congress on Cancer Immunology and Epigenetics

About this Event

Epigenetics 2019 invites all the participants from all over the world to attend "3rd Global Congress on Cancer Immunology and Epigenetics” which includes prompt keynote presentations, oral seminars, poster presentations and exhibitions.


The principal objective of this conference is to provide an international platform for cutting edge research in cancer and epigenetics.

Our aim is to provide Cancer Surgeons, Oncologists, Young researchers, Students, industrial delegates and anyone professionally involved in study of Epigenetics, Oncology, Genetics and Radiology and Imaging with an opportunity to learn about the complexity of the disease, discuss interventional procedures, look at new and advanced epigenetic practices and their efficiency and efficacy in the treatment of various Diseases and tumour extraction, and understand local realities and practical constraints in improving health-care.

About Allied Academies

Allied Academies has an enhanced features of scientific partnerships and alliances with development agencies, Institutes, leading research organizations, non-government organizations, and other entities to promote the development-oriented research across the world through live streaming, B2B and Scientific Meetings. Medical Conferences provides an excellent opportunity for the emerging scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster (for more information visit Epigenetics 2019).

Why To Attend

Oncology workshop/ Symposium, B2B and interactive sessions, CME Meetings, with industry Sponsors and Exhibitors

World-class platform to exhibit your products and services in the field of Oncology

Meet the Oncologists from 25+ countries across the globe

Interactive panel discussions and Q&A sessions

Earn up to 21 CME/ CPD credits

Live network and interaction with industry Sponsors/ experts

Well organizing scientific program with 5+ hours of networking sessions

Meet with key decision makers in the Oncology Industry worldwide and learn about the latest innovations, technologies, trends and developments in Cancer industry

Best Poster Award/ Young Research Forum.

Who Should Attend

The Epigenetics 2019, San Francisco, USA offers a platform for the Oncologists and experts both from Industry and Academia working in various sub domains of Cancer ranging from classical Oncology to the advanced technologies and image analysis in Cancer including Diagnosis and therapy.

Professionals from Oncological Laboratories, Hospitals, and Academics:

Directors, Deans, Research Professionals, Laboratory heads, Lab managers, Lab technicians, Laboratory Professionals, Medical/ Biomedical scientists, Professors, Associate Professors, Assistant Professors, Research Practicing pathologist, Research Fellows, Medical students, Nurses, Residents, working in the arena of Oncology and its allied fields,

but not limited to:

Acute Lymphoblastic Leukaemia (ALL)

Breast Cancer

Melanoma Skin Cancer

Non-Hodgkin Lymphoma

Renal Cell (Kidney) Cancer

Lung Cancer

Prostate Cancer

Bone Cancer

Liver Cancer

Brain and Spinal Cord Tumors etc.

Industry partners and professionals, vendors in the arena of :


Diagnostic Devices

Imaging Products

Oncology Lab Equipment Manufacturers

Commercial Diagnostics Laboratories

Clinical Research Organizations (CRO)

Lab reagents, Assays and Kits suppliers

Oncology service providers etc.

Leading companies with Clinical laboratory/ Oncology Services

Genomic Health

Bio-Reference Laboratories


Laboratory Corporation of America

Myriad Genetics


Quest Diagnostics

Siemens Healthineers

Sonic Healthcare Limited

Spectra Laboratories

SYNLAB International GMBH

­ Top Oncology Therapies:






















Scientific Sessions

Session 1: Cancer Immunology & Immunotherapy

Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. The immune system helps your body fight infections and other diseases. It is made up of white blood cells and organs and tissues of the lymph system. Cancer immunology is an interdisciplinary branch of biology concerned with the role of the immune system in the progression and development of cancer; the most well-known application is cancer Immunotherapy, where the immune system is used to treat cancer. Cancer immunosurveillance appears to be an important host protection process that decreases cancer rates through inhibition of carcinogenesis and maintaining of regular cellular homeostasis. It has also been suggested that immunosurveillance primarily functions as a component of a more general process of cancer immunoediting, It induces selection for certain tumour cells, which loose dominant tumour-specific antigens allowing the tumour to progress. It has three main phases: elimination, equilibrium and escape. Immunotherapy is a biological therapy. Biological therapy is a type of treatment that uses substances made from living organisms to treat cancer.

Types of Immunotherapy that help the immune system act directly against the cancer include:

Checkpoint inhibitors

Adoptive cell transfer

Monoclonal antibodies

Treatment vaccines


Session 2: Immuno-Oncology

Immuno-oncology is the study and development of treatments that take advantage of the body’s immune system to fight cancer. Our immune system is a complex network of organs, cells and molecules that protects us from foreign substances such as bacteria and viruses that can cause infection. Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body’s own immune system fight cancer. Its goal is to provide the unmet need of long-term survival in patients with advanced cancers. In addition to finding and destroying foreign substances, the immune system can also locate and attack abnormal cells.

There are two main parts of the immune system:

Humoral, also called antibody-mediated, in which B-cells (a type of white blood cell called a lymphocyte) make antibodies (specific blood proteins) that identify and destroy foreign substances.

Cell-mediated, in which T-cells (another type of white blood cell or lymphocyte) identify and destroy abnormal cells, including those that are cancerous.

Both an overactive and an underactive immune system can be harmful. Our growing understanding of the health benefits of a balanced immune system has led to the development of immunotherapies as a treatment approach for many types of cancer.

Session 3: Cancer Therapy & Treatments

Cancer can be treated. The choice of therapy depends upon the location and grade of the tumor and the stage of the disease, as well as the state of the patient. A number of experimental cancer treatment are also under development. Under current estimates, two in five people will have cancer at some point in their lifetime.

Complete removal of the cancer without damage to the rest of the body is the ideal goal of treatment and is often the goal in practice. Sometimes this can be accomplished by surgery, but the propensity of Cancers to invade adjacent tissue or to spread to distant sites by microscopic metastasis often limits its effectiveness; and chemotherapy and radiotherapy can have a negative effect on normal cells. Therefore, cure with non-negligible adverse effects may be accepted as a practical goal in some cases; and besides curative intent, practical goals of therapy can also include: suppressing the cancer to a subclinical state and maintaining that state for years of good quality of life (that is, treating the cancer as a chronic disease), and Palliative care without curative intent (for advanced-stage metastatic cancers).Types of treatments are:


Radiation therapy


Targeted therapies


Hormonal therapy

Session 4: Cancer Stem Cell Therapy

Cancer stem cells were first identified by Scientist John Dick in acute myeloid leukaemia. Cancer stem cells (CSCs) are cancer cells (found within tumours or haematological cancers) that shows characteristics associated with normal stem cells, driven from tumorigenesis and gives rise to a large population of differentiated progeny that make up the bulk of a tumour, but lack tumorigenic potential, therefore they are Tumour forming Cancer are rare immortal cells within a tumour that can both self-renew by dividing and give rise to many cell types that constitute the tumour, and can therefore form tumours.

CSCs generate tumours through the stem cell processes of self-renewal and differentiate into multiple cell types. Oncology Meetings have to explore that, CSCs have recently identified in several solid tumours such as in Brain, Breast Cancer, Colon, Ovary, Pancreas, Prostate, Melanoma and Multiple Myeloma. Such cells have been found in various types of human tumours and might be attractive targets for Cancer treatment.

Stem Cell Transplantation for Cancer

Cancer Stem Cells Epigenetics

Embryonic Stem Cells

Cancer Stem Cells in Solid Tumors

Session 5: Organ-Specific Cancers

Cancer is based on the location of cancer cells occur in particular organ. There are more than 200 different types of cancer diagnosed. Among them, Lung cancer, breast cancer is the most common cancer diagnosed in 2015. Apart from this prostate cancer, colon cancers, bladder cancer, breast cancer are the most common type cancer. The rare types of cancers are which affect the bone known as Bone Cancer. Depending upon the location of cancer the causes, symptoms, and method of treatments vary. Carcinoma, Sarcoma, leukaemia, lymphoma, and melanoma are the types of cancerfound in different organs.

Haemato oncology

Head & Neck Oncology

Urological Oncology

Session 6: Immuno-Informatics

Immunoinformatics applies informatics techniques to the study of molecules of the immune system. The principal goal of this study is the efficient and effective prediction of immunogenicity. This may be done at the level of epitopes, subunit vaccines, or weakened or inactive pathogens. A large volume of data relevant to immunology research has accumulated due to sequencing of genomes of the human and other model organisms. A huge amount of clinical and epidemiologic data is being deposited in various scientific literature and clinical records. Thus the need to handle this rapidly growing immunological resource has given rise to the field known as immunoinformatics. Immunoinformatics, otherwise known as computational immunology, is the interface between computer science and experimental immunology. It represents the use of computational methods and resources for the understanding of immunological information. It not only helps in dealing with huge amount of data but also plays a great role in defining new hypotheses related to immune responses.

Session 7: Cancer Biology & Genetics

Cancer is caused when cells within the body accumulate genetic mutations and start to grow in an uncontrolled manner. Understanding how cancer develops and progresses, including how gene mutations drive the growth and spread of cancer cells, and how tumours interact with their surrounding environment, is vital for the discovery of new targeted cancer treatments.

Tumor Biology

Cancer Epigenetics

Oncogenes & Proto-oncogenes

Tumour Suppressor Genes

Session 8: Immunological Techniques

Immunological techniques are the wide varieties of methods and specialized experimental protocols devised by immunologists for inducing, measuring, and characterizing immune responses. They allow the immunologists to alter the immune system through cellular, molecular and genetic manipulation. Most immunological techniques available are focused on the study of the adaptive immune system. They classically involve the experimental induction of an immune response using methods based on vaccination protocols. Immunological techniques are set of methods which mainly used for identification processes like infectious diseases and applied in investigational protocols to know the measurements and categorization of immune responses. Most of the techniques handle production and use of antibiotics to detect specific proteins in biological samples. These techniques allow immunologist to modify the immune system mainly by cellular, molecular and genetic manipulation.



Radioimmunoassay (RIA)


Agglutination based methods

Immunoblotting techniques

Immunofluorescence techniques

Enzyme-linked immunosorbent assay (ELISA )

Session 9: Cancer Immunodiagnosis

Tumor-associated antigens (TAAs) can be useful tumor markers in the diagnosis and management of various tumors. An ideal tumor marker is released only from tumor tissue, is specific for a given tumor type (to direct diagnostic assessment), is detectable at low levels of tumor cell burden, has a direct relationship to the tumor cell burden and the marker concentration in blood or other body fluid, and is present in all patients with the tumor. Most tumors release antigenic macromolecules into the circulation that can be detected by immunoassay. Although useful in monitoring patients for tumor recurrence after therapy, no tumor marker has undisputed specificity or sensitivity for application in early diagnosis or mass cancer screening programs.

Carcinoembryonic antigen (CEA)


Beta- Subunit of human chorionic gonadotropin (Beta-HCG)

Prostate-specific antigen (PSA)

CA 125

Radiolabeled monoclonal antibody B72.3

Session 10: Surgical & Radiation Oncology

Surgical oncology is the branch of surgery applied to cancer; it focuses on the surgical management of tumors, especially cancerous tumors. As one of several modalities in the management of cancer, the specialty of surgical oncology, before modern medicine the only cancer treatment with a chance of success, has evolved in steps similar to medical oncology (pharmacotherapy for cancer), which grew out of hematology, and radiation oncology, which grew out of radiology. The proliferation of cancer centers will continue to popularize the field, as will developments in minimally invasive techniques, palliative surgery, and neo-adjuvant treatments. Radiation oncology is one of the three primary specialties, the other two being surgical and medical oncology, involved in the treatment of cancer. A Radiation Oncologist is a specialist physician who uses ionizing radiation (such as megavoltage X-rays or radionuclides) in the treatment of cancer. Brachytherapy is an advanced cancer treatment. Radioactive seeds or sources are placed in or near a tumour itself, giving a high radiation dose to the tumour while reducing the radiation exposure in the surrounding healthy tissues. External beam therapy (EBT), also called external radiation therapy, is a method for delivering a beam or several beams of high-energy x-rays to a patient's tumour. Intraoperative radiation therapy or IORT is the application of therapeutic levels of radiation to the tumour bed while the area is exposed during surgery.

Session 11: Cancer Nursing and Care

Oncology nurses work in a multi-disciplinary team, in a variety of settings, from the inpatient ward, to the bone marrow transplant unit, through to the community. Oncology nurses often serve as your first line of communication, and help coordinate the many aspects of your care throughout cancer treatment. They may perform a number of duties. An Oncology Nurse provides care for cancer patients and those at risk for getting the disease. Oncology nurses must manage both the symptoms of a patient’s disease and the side effects of various cancer treatments. They monitor physical conditions, prescribe medication, and administer chemotherapy and other treatments. Oncology nurses witness much suffering but this stress is offset by the long-term relationships they often develop with patients and their families.

Pediatric Hematology Cancer Nursing

Surgical Cancer Nursing

Chemotherapy Biotherapy

Breast Care Nursing

Assisting in Cancer Care

Addictions Nursing

Cancer Nursing Partnership

Oncology- Diabetes In Control

Session 12: Cancer Prevention & Research

Cancer prevention is defined as active measures to decrease the risk of cancer. Most of cancer cases are due to environmental risk factors, and many, but not all, of these environmental factors are controllable lifestyle choices. An individual's risk of developing cancer can be substantially reduced by healthy behaviour. Cancer Prevention Research comprises preclinical, clinical and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences.


Avoiding Risk Factors

Changing Lifestyle Choices

Preclinical & Clinical Research

Early Detection Research


Chemo preventive Measures

Session 13: Epigenetics

Epigenetics is the study of heritable phenotype changes that do not involve alterations in the DNA sequence. Epigenetics most often denotes changes that affect gene activity and expression, but can also be used to describe any heritable phenotypic change. Such effects on cellular and physiological phenotypic traits may result from external or environmental factors, or be part of normal developmental program. The standard definition of epigenetics requires these alterations to be heritable, either in the progeny of cells or of organisms. The term also refers to the changes themselves: functionally relevant changes to the genome that do not involve a change in the nucleotide sequence. Examples of mechanisms that produce such changes are DNA methylation and histone modification, each of which alters how genes are expressed without altering the underlying DNA sequence. Gene expression can be controlled through the action of repressor proteins that attach to silencer regions of the DNA. These epigenetic changes may last through cell divisions for the duration of the cell's life, and may also last for multiple generations even though they do not involve changes in the underlying DNA sequence of the organism; instead, non-genetic factors cause the organism's genes to behave differently.

Session 14: Cancer Epigenetics

Cancer epigenetics is the study of epigenetic modifications to the DNA of cancer cells that do not involve a change in the nucleotide sequence. Epigenetic alterations may be just as important, or even more important, than genetic mutations in a cell's transformation to cancer. In cancers, loss of expression of genes occurs about 10 times more frequently by transcription silencing (caused by epigenetic promoter hypermethylation of CpG islands) than by mutations. As Vogelstein et al. point out, in a colorectal cancer there are usually about 3 to 6 driver mutations and 33 to 66 hitchhiker or passenger mutations. However, in colon tumors compared to adjacent normal-appearing colonic mucosa, there are about 600 to 800 heavily methylated CpG islands in promoters of genes in the tumors while these CpG islands are not methylated in the adjacent mucosa. Manipulation of epigenetic alterations holds great promise for cancer prevention, detection, and therapy. In different types of cancer, a variety of epigenetic mechanisms can be perturbed, such as silencing of tumor suppressor genes and activation of oncogenes by altered CpG island methylation patterns, histone modifications, and deregulation of DNA binding proteins. Several medications which have epigenetic impact are now used in several of these diseases.

Session 15: Epigenetics Mechanism

During meiosis, most epigenetic modifications to the genome are erased. However, some of the epigenetic structures remain and the expression programme of some genes is maintained. The new generation inherits the basic DNA sequence along with the programme of gene expression created by the parents’ epigenetic machinery. These mechanisms are regulated by proteins which tell the machinery needed for transcription where and when they can access the DNA sequence, and transcribe the DNA into RNA. Several epigenetic mechanisms exist to appropriately allow the expression of genes. These mechanisms include:

DNA methylation

Histone modification

non-coding RNA

Session 16: Epigenetic Diseases

Diseases, such as cancer, involve epigenetic changes, it seems reasonable to try to counteract these modifications with epigenetic treatments. These changes seem an ideal target because they are by nature reversible, unlike DNA sequence mutations. The most popular of these treatments aim to alter either DNA methylation or histone acetylation. Inhibitors of DNA methylation can reactivate genes that have been silenced. Two examples of these types of drugs are 5-azacytidine and 5-aza-2?-deoxycytidine. These medications work by acting like the nucleotide cytosine and incorporating themselves into DNA while it is replicating. After they are incorporated into DNA, the drugs block DNMT enzymes from acting, which inhibits DNA methylation. Drugs aimed at histone modifications are called histone deacetylase (HDAC) inhibitors. HDACs are enzymes that remove the acetyl groups from DNA, which condenses chromatin and stops transcription. Blocking this process with HDAC inhibitors turns on gene expression. The most common HDAC inhibitors include phenylbutyric acid, SAHA, depsipeptide, and valproic acid.

Session 17: Epigenetic Biomarkers in Cancer

Epigenetic regulation is involved in almost all developmental processes of mammalian cells from fertilisation, implantation, and differentiation during embryonic development to aging and carcinogenesis. Different stages of development are characterized by differences in epigenetic signatures, and variations in epigenetic patterns may also be associated with specific stages of disease. Carcinogenesis is a multistep process, the detection of changes in epigenetic profiles can be exploited to differentiate not only between different types of malignancies but also between different stages of cancer progression. Epigenetic biomarkers hold great promise to become more conclusive diagnostic and prognostic biomarkers for different cancers. DNA methylation is the most studied area of epigenetics; DNA methylation biomarkers will play a prominent role. Epigenetic regulation plays a major role in cancer formation, and analysis of epigenetic biomarkers has great potential to become clinically relevant. More studies are required to further develop and evaluate the clinical application of epigenetic biomarkers.

Session 18: Cancer Pharmacology

Cancer pharmacology plays a key role in drug development. In both the laboratory and the clinic, cancer pharmacology has had to adapt to the changing face of drug development by establishing experimental models and target orientated approaches. It also focuses on developing experimental approaches to the clinical treatment of cancer through research that bridges the fields of molecular carcinogenesis, biochemical pharmacology, radiation biology, and clinical pharmacology. It generally involves the pharmacological and oncological aspects of drugs at both an experimental and clinical level.

Cancer Drug Targets

Molecular Carcinogenesis

Biochemical Pharmacology

Clinical Pharmacology

Pharmacokinetics and Pharmacodynamics

Session 19: Cancer Pharma Industry

Cancer is one of the greatest health challenges and a leading cause of death in every corner of the world. The global market for Cancer drugs is predicted to grow twice as fast as that of other pharmaceuticals over the next few years. Top companies include Janssen biotech, Takeda oncology, Boehringer Ingelheim, Roche, Novartis, Celgene, Johnson & Johnson, and Amgen. The Cancer industry is the most commonly valuable business in the USA. It has been noticed that there are 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US in the year 2014. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research mainly as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with the rise of 39 percent to $173 billion by the upcoming year that is 2020. The most common motto of the cancer industry is it employs too many people and produces too much income to allow a cure to be found.

Session 20: Cancer Pain Management, Survival and Awareness

Cancer pain treatment purposes to release pain with slight adverse treatment effects, allowing the person a good quality of life and level of function and a relatively painless death. Though 80-90 percent of cancer pain can be controlled, half of the people with cancer pain in the developed world and more than 80% of people with cancer worldwide receive less than best care. Cancer changes over time, and pain managing needs to reflect this. Some different types of treatment may be required as the disease progresses. Pain managers should clearly explain to the person the cause of the pain and the various treatment possibilities and should consider, as well as drug therapy, directly modifying the underlying disease, raise the pain threshold, interrupting, destroying or stimulating pain pathways, and suggesting lifestyle modification. Cancer survival rates vary by the type of cancer, stage at diagnosis, treatment was given and many other factors, including country. Survival rate can be measured in several ways, median life expectancy having advantages over others in terms of meaning for people involved, rather than as an epidemiological measure.

"Please contact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for:

- Multiple participant discounts

- Price quotations or visa invitation letters

- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)

- Event sponsorship


Prices may go up any time. Service fees included in pricing.


This event is brought to you by:

Pulsus Group - NewYorkEventsList






Share with friends

Date and Time


Venue will be informed to the Registered Participants


San Francisco, 94103

View Map

Save This Event

Event Saved